---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-017363"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:12:52.795371+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BriaCell signs $4M stock purchase and CRO agreement with Prevail for pivotal breast cancer study

## Summary
- Prevail InfoWorks to serve as CRO for BriaCell's pivotal advanced metastatic breast cancer study, expected in 2023.
- BriaCell receives $4M from Prevail Partners for 463,408 shares at $8.63, a 20% premium to 30-day VWAP.
- Upfront payment of $5,379,945 under MST Agreement, plus milestone fees; funds used to pay InfoWorks.
- Stock purchase expected to close on or about May 19, 2023, subject to TSX approval.

## SEC filing metadata
- accession: 0001493152-23-017363
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223017363/0001493152-23-017363-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223017363/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-017363
- JSON: https://secwatch.observer/filing/0001493152-23-017363.json
- Plain text: https://secwatch.observer/filing/0001493152-23-017363.txt

## Key facts
- Material Agreements
  BriaCell Therapeutics Corp. entered into Master Service and Technology Agreement with Prevail InfoWorks, Inc. valued at $5,379,945 (effective 2023-05-09).
  - Action: entry
  - Counterparty: Prevail InfoWorks, Inc.
  - Value: $5,379,945
  - Effective: 2023-05-09
  source text: On May 9, 2023, BriaCell Therapeutics Corp. (the “Company”) entered into a Master Service and Technology Agreement (the “MST Agreement”) with Prevail InfoWorks, Inc. (“InfoWorks”) pursuant to which InfoWorks will provide clinical services and technologies for the Company’s upcoming pivotal study in advanced metastatic breast cancer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610820/000149315223017363/0001493152-23-017363-index.htm
- Material Agreements
  BriaCell Therapeutics Corp. entered into Stock Purchase Agreement with Prevail Partners, LLC valued at $4,000,000 (effective 2023-05-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Prevail Partners, LLC
  - Value: $4,000,000
  - Effective: 2023-05-12
  source text: On May 12, 2023, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Prevail Partners, LLC, an investment fund and affiliate of InfoWorks, pursuant to which the Company agreed to issue 463,408 common shares (the “Shares”) for an aggregate purchase price of $4,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1610820/000149315223017363/0001493152-23-017363-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.